Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: National Institute of General Medical Sciences (NIGMS)
• Treatments: Anesthetics; Fentanyl; Insulin; Propofol

Criteria

Inclusion Criteria:

• Inclusion criteria include patients of adult age

• American Society of Anesthesiologists Class I, II, or III, and undergoing elective surgical procedures requiring general anesthesia

• Body mass index greater than 35

Exclusion Criteria:

• Patients with evidence of hepatic, renal, or cardiovascular dysfunction

• History of difficult tracheal intubation, or adverse reaction to anesthesia shall be excluded from the study

• Patients taking prescribed or over-the-counter anxiolytics, narcotics, or sleeping aids, will also be excluded